About US
Contact us
-
Retailers pull Johnson & Johnson's baby powder products after asbestos scareJohnson & Johnson investors were sent reeling when the drugmaker pulled some ofits baby powder products off shelves after "sub-trace" amounts of asbestos were found in certain lots. Now, retailer2019/10/14
-
Clinuvel obtains US approval for rare disorder drug ScenesseAustralia-based Clinuvel Pharmaceuticals has received the US Food and Drug Administration (FDA) approval for the use of Scenesse (16mg afamelanotide) to treat erythropoietic protoporphyria (EPP), whi2019/10/11
-
UCB to acquire Ra Pharmaceuticals in $2.1bn dealBelgian biopharmaceutical firm UCB has signed a merger agreement to acquire US-based Ra Pharmaceuticals for $48 per share, totalling $2.1bn in cash. Founded in 2008, Ra Pharma uses its peptide chemis2019/10/11
-
ICER finds lack of evidence to support blockbuster drug price hikesA report by the Institute of Clinical and Economic Review (ICER) has determined that seven of the nine top-selling drugs in the US had limited new clinical evidence of greater patient benefit to just2019/10/10
-
GSK and Lyell partner to develop cell therapies for cancerGlaxoSmithKline (GSK) has partnered with US-based biotechnology firm Lyell Immunopharma to develop technologies to boost cancer cell therapies. Under the five-year partnership, GSK’s cell and gene th2019/10/10
-
J&J’s Janssen to pay $8bn in Risperdal anti-psychotic drug lawsuitA jury at Philadelphia Court of Common Pleas has ordered Johnson & Johnson (J&J) subsidiary Janssen Pharmaceuticals to pay $8bn in punitive damages over its marketing of Risperdal, an anti-ps2019/10/9
-
Novartis receives FDA approval for Beovu to treat wet AMDNovartis has secured the US Food and Drug Administration (FDA) approval for the use of its Beovu (brolucizumab) medicine to treat wet age-related macular degeneration (AMD). Wet AMD is a degenerative2019/10/9
-
Pfizer licenses Akcea’s ANTPTL3-targetting drug for $250mPfizer and Ionis subsidiary Akcea have signed a global exclusive licensing agreement for antisense therapy AKCEA-ANGPTL3-LRx. According to the terms of the agreement, Akcea and Ionis will receive $252019/10/8
-
UK Government invests £35m into researching adolescent mental healthThe UK Government has launched a research project into understanding the causes of mental health problems in teenagers and young adults, including the genetics and societal influences underpinning wh2019/10/8
-
J&J to invest $500m in HIV and TB therapies researchJohnson & Johnson (J&J) has announced plans to invest over $500m towards research and development of HIV and tuberculosis (TB) vaccines. Set to be used over the coming four years, the investm2019/9/30